Alnylam Pharmaceuticals Inc Capital Reinvestment Ratio
Alnylam Pharmaceuticals Inc capital reinvestment ratio. Alnylam Pharmaceuticals Inc (ALNY) has a Capital Reinvestment Ratio of 0.14x as of December 2025, meaning it reinvests 0% of its operating cash flow ($163.56 Million) in capital expenditures ($23.29 Million). See ALNY free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Alnylam Pharmaceuticals Inc (2007–2025)
Capital reinvestment ratio of Alnylam Pharmaceuticals Inc from 2007 to 2025. This chart tracks Alnylam Pharmaceuticals Inc's Capital Reinvestment Ratio across 4 annual periods. See Alnylam Pharmaceuticals Inc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
Alnylam Pharmaceuticals Inc Capital Reinvestment Ratio by Year (2007–2025)
Alnylam Pharmaceuticals Inc capital reinvestment ratio by year from 2007 to 2025. For the full cash flow conversion analysis, see how efficiently does Alnylam Pharmaceuticals Inc generate cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.11x | $524.08 Million | $58.70 Million | ▼ -81.2% |
| 2023 | 0.60x | $104.16 Million | $62.21 Million | ▲ +263.4% |
| 2008 | 0.16x | $65.49 Million | $10.76 Million | ▲ +314.7% |
| 2007 | 0.04x | $196.52 Million | $7.79 Million | — |